← Back to Search

Cannabinoid

25 mg for Healthy Subjects

Phase < 1
Waitlist Available
Research Sponsored by Castleton University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

This study is evaluating whether CBD might have a positive effect on heart rate variability.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in heart rate variability (HRV) as assessed by frequency-domain analysis: LF/HF ratio.
Change in heart rate variability (HRV) as assessed by frequency-domain analysis: high-frequency (HF).
Change in heart rate variability (HRV) as assessed by frequency-domain analysis: low-frequency (LF).
+4 more

Side effects data

From 2017 Phase 2 trial • 13 Patients • NCT02818777
85%
Diarrhea
69%
Somnolence
62%
Fatigue
38%
Elevated liver function tests
31%
Weight gain
23%
Dizziness
23%
Abdominal pain
15%
weight loss
15%
nausea
15%
anorexia
15%
headache
15%
increased appetite
8%
fever
8%
weakness
8%
vomiting
8%
flatulence
8%
gastroesophageal reflux
8%
allergic reaction
8%
spasm
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cannabidiol

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 50 mgExperimental Treatment1 Intervention
Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
Group II: 25 mgExperimental Treatment1 Intervention
Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
Group III: 200 mgExperimental Treatment1 Intervention
Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
cannabidiol
2010
Completed Phase 3
~150

Find a Location

Who is running the clinical trial?

Castleton UniversityLead Sponsor
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Cannabidiol and Autonomic Function at Rest
Andrea Corcoran 2021. "Cannabidiol and Autonomic Function at Rest". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04731779.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top